Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV001012791 | SCV001173291 | uncertain significance | Hereditary cancer-predisposing syndrome | 2018-09-24 | criteria provided, single submitter | clinical testing | The p.K6E variant (also known as c.16A>G), located in coding exon 1 of the RAD50 gene, results from an A to G substitution at nucleotide position 16. The lysine at codon 6 is replaced by glutamic acid, an amino acid with similar properties. Studies conducted in yeast showed this alteration had deficient but not absent function (Alani E et al. Cell. 1990 May;61:419-36). In addition, this alteration was unable to rescue a lethal phenotype in mouse RAD50 null embryonic stem cells (Bender CF et al. Genes Dev. 2002 Sep;16:2237-51). This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |